Abstract
Pharmacokinetic parameters and efficacy prediction indexes (Cmax/MIC90 and AUC0−24/MIC90) of an enrofloxacin hydrochloride (ENR-HCl) veterinary product soluble in water were determined in healthy broiler chickens of both sexes after a single oral dose of ENR-HCl (equivalent to 10 mg ENR base/kg bw). Monte Carlo simulations targeting Cmax/MIC90 = 10 and AUC0−24/MIC90 =125 were also performed based on a set of MIC (minimum inhibitory concentration) values of bacterial strains that induce common clinical diseases in broiler chickens and that showed to be susceptible to ENR-HCl. Plasma concentrations of ENR and its main metabolite ciprofloxacin (CIP) were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Plasma concentration-time curves were found to fit a non-compartmental open model. The ratio of the area under the plasma concentration-time curve (AUC) of CIP/ENR was 4.91%. Maximum plasma concentrations of 1.35 ± 0.15 μg/mL for ENR-HCl and 0.09 ± 0.01 μg/mL for CIP were reached at 4.00 ± 0.00 h and 3.44 ± 1.01 h, respectively. Areas under the plasma vs. time concentration curve in 24 h (AUC0−24) were 18.91 ± 1.91 h × μg/mL and 1.19 ± 0.12 h × μg/mL for ENR-HCl and CIP, respectively. Using a microbroth dilution method, the minimum inhibitory concentration (MIC90) values were determined for ENR-HCl for 10 bacterial strains (Mycoplasma gallisepticum, Mycoplasma synoviae, Avibacterium paragallinarum, Clostridium perfringens, Escherichia coli, Pseudomonas aeruginosa, Salmonella ser. Enteritidis, Salmonella ser. Gallinarum, Salmonella ser. Pullorum, and Salmonella ser. Typhimurium), which are the most common causes of infectious clinical diseases in broiler chickens. In summary, the PK/PD ratios and Monte Carlo simulation were carried out for ENR-HCl in poultry, which due to its solubility was administered in drinking water. The PK/PD efficacy prediction indexes and Monte Carlo simulations indicated that the ENR-HCl oral dose used in this study is useful for bacterial infections in treating C. perfringens (Gram-positive), E. coli and S. ser. Enteritidis (Gram-negative) and M. gallisepticum bacteria responsible for systemic infections in poultry, predicting a success rate of 100% when MIC ≤ 0.06 μg/mL for E. coli and S. ser. Enteritidis and MIC ≤ 0.1 μg/mL for M. gallisepticum. For C. perfringens, the success rate was 98.26% for MIC ≤ 0.12. However, clinical trials are needed to confirm this recommendation.
Highlights
Fluoroquinolones (FQs) were developed to overcome the limitations exhibited by several antibacterial agents
Enrofloxacin hydrochloride (ENR-HCl) (1-cyclopropyl-7-(4ethylpiperazin-1-yl) -6-fluoro-4-oxoquinoline-3-carboxylic acid; hydrochloride; CAS No 112732-17-9) is a FQ exclusively used in veterinary medicine that is metabolized by the liver into ciprofloxacin (CIP), which is an equipotent metabolite [2]
Our findings indicated mean residence times (MRTs) of 10.60 ± 0.32 h and 10.59 ± 0.42 h for ENR-HCl and CIP, respectively (Table 1), which are similar to those values reported for ENR-HCl in turkeys [3] and broiler chickens [20]
Summary
Fluoroquinolones (FQs) were developed to overcome the limitations exhibited by several antibacterial agents. Their broad spectrum of antibacterial activity, good oral availability and distribution in tissues, longer elimination half-life and considerably reduced toxicity make FQs the preferred antimicrobial agent for treating a broad variety of bacterial infections, in veterinary use and in humans [1]. The potential usefulness of ENR-HCl as an antibacterial agent for the treatment of common infections in poultry requires detailed information on PK/PD indices and the optimum level of drug exposure associated with the susceptibility of the agent to thereby limit the development of resistance in target pathogens [6]. ENR should only be used based on culture and antimicrobial susceptibility testing (C&AST)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.